---
title: "《大行》美银证券升科伦博泰目标价至 479 元  下调收入预测"
description: "美银证券将科伦博泰的目标价从 470 元上调至 479 元，同时下调 2026 年和 2027 年的收入预测，分别减少 5% 和 6%。该公司旗下的 sac-TMT 药物近期获批用于治疗 HR 阳性/HER2 阴性乳腺癌，并已纳入国家医保目录，但由于医保价格调整，年度治疗费用假设被下调。美银证券重申对该公司的「中性」评级，认为业务进展符合预期，但面临激烈竞争。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275711706.md"
published_at: "2026-02-12T06:47:51.000Z"
---

# 《大行》美银证券升科伦博泰目标价至 479 元  下调收入预测

> 美银证券将科伦博泰的目标价从 470 元上调至 479 元，同时下调 2026 年和 2027 年的收入预测，分别减少 5% 和 6%。该公司旗下的 sac-TMT 药物近期获批用于治疗 HR 阳性/HER2 阴性乳腺癌，并已纳入国家医保目录，但由于医保价格调整，年度治疗费用假设被下调。美银证券重申对该公司的「中性」评级，认为业务进展符合预期，但面临激烈竞争。

美银证券研究报告指，科伦博泰生物-B(06990.HK) 旗下 sac-TMT(TROP-2 ADC) 近期获国家药品监督管理局批准，用於二线及以上 HR 阳性/HER2 阴性乳腺癌的治疗，是该药物第四项在内地获批的适应症。

同时，该药物用於三线三阴性乳腺癌及三线 EGFR 突变非小细胞肺癌的适应症，已自今年 1 月起纳入国家医保药品目录。不过，由於国家医保目录价格调整，该行下调 sac-TMT 的年度治疗费用假设。

该行将 2026 及 2027 年的收入预测分别下调 5% 及 6%，目标价由 470 元升至 479 元，重申「中性」评级，反映业务进展符合预期，但同时被日益激烈的竞争所抵消。

### Related Stocks

- [06990.HK - 科伦博泰生物-B](https://longbridge.com/zh-CN/quote/06990.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administratio | [Link](https://longbridge.com/zh-CN/news/275096325.md) |
| Collage Becomes the First Benefits-Connected HR Platform in Canada to Embed Payroll, Powered by Nmbr | Collage has launched Collage Payroll, becoming the first benefits-connected HR platform in Canada to embed payroll, in p | [Link](https://longbridge.com/zh-CN/news/276121845.md) |
| REG - Midwich Group PLC - CFO Appointment – Additional Information | Midwich Group PLC has announced the appointment of a new Chief Financial Officer (CFO). The announcement includes a comp | [Link](https://longbridge.com/zh-CN/news/276328871.md) |
| Boxing-Floyd Mayweather to come out of retirement - again | Floyd Mayweather, the former multi-weight world boxing champion, is set to come out of retirement for his first official | [Link](https://longbridge.com/zh-CN/news/276504029.md) |
| Barclays Remains a Buy on BorgWarner (BWA) | Barclays analyst Dan Levy has maintained a Buy rating on BorgWarner (BWA) with a price target of $70.00, while the stock | [Link](https://longbridge.com/zh-CN/news/276534773.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。